ObesityPhase 1NCT04081337
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
A Phase 1 study testing Tirzepatide in people with Obesity, run by Eli Lilly and Company at 1 site in United States.
Trial summary
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Obesity
- What is being tested?
- Tirzepatide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 55 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jul 2020to 26 May 2022
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Have body mass index of 30 to 45 kilograms per square meter (kg/m²), inclusive
- Have a stable body weight in the past 1 month prior to screening
- Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff
Who cannot join
- Have undergone gastric bypass or bariatric surgery
- Have a diagnosis of type 2 diabetes
- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data
- Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
- Have any lifetime history of a suicide attempt
- Patient Health Questionnaire-9 (PHQ-9) score of 15 or more at screening
- Positive responses to selected items on the Columbia Suicide Severity Rating Scale (C-SSRS)
Trial locations and contacts
1 site in 1 country.
United States1 site
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808
About this study
Official title: A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
- Conditions
- Obesity
- Being tested
- Tirzepatide, Placebo
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TirzepatideDrug
Also called LY3298176
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants received placebo once weekly (QW) by Subcutaneous (SC) injection. Receives: Drug: Placebo |
| 15 Milligram (mg) Tirzepatide | Experimental | Participants received 15 mg of tirzepatide QW by SC injection. Receives: Drug: Tirzepatide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Measured: Baseline, Week 18
Secondary outcomes (15)
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 [Liter/24hour] / total VO2 [Liter/24hour]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Sleep RQ
Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
RQ<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ <0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented.
- Protein Oxidation = 6.25*[urinary nitrogen]
- Fat Oxidation = 1.689*[total oxygen consumption (VO2)] - 1.689*[total carbon dioxide production (VCO2)] - 0.324*[protein oxidation]
- Carbohydrate Oxidation = 4.113*[VCO2] - 2.907*[VO2] - 0.375*[protein oxidation].
Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day).
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Body Weight (BW)
Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment*Time, Participant and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat-Free Mass
Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat Mass
Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Percentage of Body Fat Mass
The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Fasting Insulin Resistance
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin).
HOMA-IR= [Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18 during standardized mixed meal tolerance test
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of <2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
Total AUC from time zero to 4 hours after start of the meal [AUC0-4 hours]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Measured: Baseline, Week 18
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment*Time, Participant and Random Error as variables.
Measured: Baseline, Week 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2019
- Study start9 Jul 2020
- Primary completion26 May 2022
- Study completion26 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04081337
- Sponsor's protocol ID
- 17092
- Other IDs
- I8F-MC-GPGU
- Status last verified
- May 2023
- First submitted
- 5 Sep 2019
- Last updated
- 8 Feb 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects
- ClinicalTrials.gov ID
- NCT04081337
- Acronym / sponsor ID
- 17092
- Conditions
- Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 9 Jul 2020 (actual)
- Primary completion
- 26 May 2022 (actual)
- Study completion
- 26 May 2022 (actual)
- First posted
- 9 Sep 2019 (actual)
- Results
- Posted 8 Feb 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboParticipants received placebo once weekly (QW) by Subcutaneous (SC) injection. |
| 15 Milligram (mg) Tirzepatide | Experimental | Drug: TirzepatideParticipants received 15 mg of tirzepatide QW by SC injection. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Have body mass index of 30 to 45 kilograms per square meter (kg/m²), inclusive
- Have a stable body weight in the past 1 month prior to screening
- Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff
Key exclusion criteria (7 listed)
- Have undergone gastric bypass or bariatric surgery
- Have a diagnosis of type 2 diabetes
- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data
- Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
- Have any lifetime history of a suicide attempt
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TirzepatideAlso: LY3298176Administered SC | Drug | 15 Milligram (mg) Tirzepatide |
| PlaceboAdministered SC | Drug | Placebo |
Primary outcome
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
Time frame: Baseline, Week 18
SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
15 secondary outcomes
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Sleep RQ
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Weight (BW)
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat-Free Mass
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat Mass
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Percentage of Body Fat Mass
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Fasting Insulin Resistance
Time frame: Baseline, Week 18 during standardized mixed meal tolerance test
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 18
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using TirzepatideLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Tirzepatide in people with Obesity, run by Eli Lilly and Company at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Feb 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) (time frame: Baseline, Week 18). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2024.